Literature DB >> 27615390

Tau and tauopathies.

Thomas Arendt1, Jens T Stieler2, Max Holzer2.   

Abstract

Most neurodegenerative diseases are characterized by intracellular aggregates of insoluble proteins. As for the majority of these disorders, aetiology and pathogenesis are only poorly understood; current nosological concepts are largely based on these molecular signatures of protein aggregates which also provide valuable tools for neuropathological differential diagnosis. The microtubule associated protein tau is one of these proteins that form intracellular fibrillary deposits in neurons and glial cells of a large variety of disorders today collectively referred to as tauopathies. While dysfunction of tau has unequivocally been shown to be able to cause neurodegeneration, the precise mechanisms of how tau is involved in neurodegenerative disorders is still poorly understood. After research has focused for several decades on the axonal function of tau and on the fibrillar tau aggregation, more recent cell biological studies have opened up new insights into the role of tau at the synapse and in the nucleus. According to currently emerging cell biological concepts, tau might play a role in the regulation of neuronal plasticity in a wide array of neuronal networks. In addition, it might be involved in regulating genome stability. The most intriguing question relevant both to physiological and pathophysiological function of tau is the biological meaning of the large heterogeneity of isoforms of tau which apparently is a rather promiscuous molecule. The present review is divided into two parts. First, we give an overview on the molecular biology and cell biology of tau and its physiological functions. The second part deals with the pathophysiology of tau and description of tauopathies which comprise more than 20 disorders including Alzheimer's disease, progressive supranuclear palsy, cortico basal degeneration, Pick's disease and others.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Cytoskeleton; Dementia; Neurodegeneration

Mesh:

Substances:

Year:  2016        PMID: 27615390     DOI: 10.1016/j.brainresbull.2016.08.018

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  162 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Deletion of Type-2 Cannabinoid Receptor Induces Alzheimer's Disease-Like Tau Pathology and Memory Impairment Through AMPK/GSK3β Pathway.

Authors:  Lin Wang; Bing-Jin Liu; Yun Cao; Wei-Qi Xu; Dong-Sheng Sun; Meng-Zhu Li; Fang-Xiao Shi; Man Li; Qing Tian; Jian-Zhi Wang; Xin-Wen Zhou
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

3.  Tau isoform expression and phosphorylation in marmoset brains.

Authors:  Govinda Sharma; Anni Huo; Taeko Kimura; Seiji Shiozawa; Reona Kobayashi; Naruhiko Sahara; Minaka Ishibashi; Shinsuke Ishigaki; Taro Saito; Kanae Ando; Shigeo Murayama; Masato Hasegawa; Gen Sobue; Hideyuki Okano; Shin-Ichi Hisanaga
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

4.  Progressive Pathological Changes in Neurochemical Profile of the Hippocampus and Early Changes in the Olfactory Bulbs of Tau Transgenic Mice (rTg4510).

Authors:  Jieun Kim; In-Young Choi; Karen E Duff; Phil Lee
Journal:  Neurochem Res       Date:  2017-05-18       Impact factor: 3.996

5.  Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.

Authors:  Joana R F Santos; Chris Bauer; Johannes Schuchhardt; Dirk Wedekind; Katharina Waniek; Ingolf Lachmann; Jens Wiltfang; Jonathan Vogelgsang
Journal:  J Neural Transm (Vienna)       Date:  2019-02-14       Impact factor: 3.575

6.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

7.  Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice.

Authors:  Noah R Johnson; Carlo Condello; Shenheng Guan; Abby Oehler; Julia Becker; Marta Gavidia; George A Carlson; Kurt Giles; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

Review 8.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 9.  Novel Key Players in the Development of Tau Neuropathology: Focus on the 5-Lipoxygenase.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  The Microtubule-Associated Protein Tau Mediates the Organization of Microtubules and Their Dynamic Exploration of Actin-Rich Lamellipodia and Filopodia of Cortical Growth Cones.

Authors:  Sayantanee Biswas; Katherine Kalil
Journal:  J Neurosci       Date:  2017-11-22       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.